Sonoma Biotherapeutics is developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases driven by an imbalanced immune system. Founded by pioneers in Treg biology and cell therapy, the company is employing proprietary platform technologies and approaches to develop a new generation of targeted Treg cell therapies designed to induce durable immune tolerance to treat and prevent autoimmune and inflammatory diseases. Sonoma Biotherapeutics is based in South San Francisco and Seattle.

Education

Biotechnology

Sonoma Biotherapeutics

Jeff Bluestone

Jimmy Chung

Stacey Delaney

Melisa S. Medrano

Taylor Le Donne

Michael Thomas

Claire Crowther

Katie Tuckwell

Sabrina Fox-Bosetti

Melita Dvorak-Ewell

Jessica Stitt

Peter Dilaura

Doug Sheehy

Fred Ramsdell

The Leadership Team at Sonoma Biotherapeutics is responsible for guiding the company's strategic vision and operational execution. Comprising key executives including the CEO, Chief Scientific Officer, and Chief Legal Officer, this team drives innovation in developing engineered Treg therapies, oversees financial and business strategies, ensures compliance, and fosters collaboration to advance the company's mission of treating autoimmune and inflammatory diseases effectively.

Leadership Team

Scientific Research Team

Clinical Operations Team

Leadership Team

About

Team members

Other teams at Sonoma Biotherapeutics

Scientific Research Team

Clinical Operations Team